Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 10:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Etrasimod Clear all
Active, not recruiting Phase 3 Interventional

An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis

NCT03950232
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Etrasimod
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years to 80 Years
Enrollment
896 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
132
States / cities
Dothan, Alabama • Lake Elsinore, California • Lancaster, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 19, 2026, 10:15 AM EDT
Recruiting Phase 2 Interventional

Etrasimod as Prevention of Pouchitis

NCT07486921
View directory record Official record
Conditions
Pouchitis
Interventions
etrasimod, Placebo
Drug
Lead sponsor
Maia Kayal
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 19, 2026, 10:15 AM EDT
Recruiting No phase listed Observational

An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis

NCT06398626
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Etrasimod
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
26
States / cities
Mesa, Arizona • La Jolla, California • Los Alamitos, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 19, 2026, 10:15 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease

NCT04173273
View directory record Official record
Conditions
Crohn's Disease
Interventions
Etrasimod, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
192
States / cities
Dothan, Alabama • Mobile, Alabama • Peoria, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

NCT03945188
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Etrasimod, Placebo
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
16 Years to 80 Years
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
67
States / cities
Dothan, Alabama • Sun City, Arizona • Lancaster, California + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis

NCT03996369
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Etrasimod, Placebo
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
16 Years to 80 Years
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
62
States / cities
Dothan, Alabama • Mobile, Alabama • Sun City, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Oct 19, 2026, 10:15 AM EDT
Terminated Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis

NCT03155932
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
APD334
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
4
States / cities
Sacramento, California • Houston, Texas • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis

NCT02536404
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Etrasimod, Placebo
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
31
States / cities
Birmingham, Alabama • Dothan, Alabama • Thousand Oaks, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2021 · Synced Oct 19, 2026, 10:15 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection

NCT05732454
View directory record Official record
Conditions
Atopic Dermatitis, Atopic Dermatitis, Unspecified, Eczema, Eczema, Atopic
Interventions
etrasimod, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
44
States / cities
Fountain Valley, California • Laguna Hills, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Oral Etrasimod in Adult Participants With Moderate-to-Severe Alopecia Areata

NCT04556734
View directory record Official record
Conditions
Alopecia Areata
Interventions
Etrasimod, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
39
States / cities
Scottsdale, Arizona • Bryant, Arkansas • Encinitas, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis

NCT04162769
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Etrasimod 1 mg, Etrasimod 2 mg, Etrasimod matching placebo
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
35
States / cities
Tucson, Arizona • Canoga Park, California • Fountain Valley, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Oct 19, 2026, 10:15 AM EDT
Withdrawn Phase 2 Interventional

Etrasimod for Immune Checkpoint Inhibitor Diarrhea and Colitis

NCT06521762
View directory record Official record
Conditions
Immune Checkpoint Inhibitor-Related Diarrhea and Colitis
Interventions
Etrasimod, Placebo, Corticosteroids
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis

NCT02447302
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Etrasimod, Placebo
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
30
States / cities
Birmingham, Alabama • Dothan, Alabama • Thousand Oaks, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Oct 19, 2026, 10:15 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

NCT05287126
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Etrasimod
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
20
States / cities
Little Rock, Arkansas • Garden Grove, California • Loma Linda, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 19, 2026, 10:15 AM EDT
Recruiting Phase 2 Interventional

A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis

NCT07470879
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Etrasimod
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 11 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
7
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis

NCT04607837
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Etrasimod, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
132
States / cities
Dothan, Alabama • Peoria, Arizona • Sun City, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of Oral Etrasimod in Adult Participants With Eosinophilic Esophagitis

NCT04682639
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Etrasimod, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
221
States / cities
Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 85 more
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Oct 19, 2026, 10:15 AM EDT